MN553 Unit 5 Sample Paper

Selecting Oral Anticoagulation for New Atrial Fibrillation in a 68-Year-Old Woman: Apixaban Dosing, Monitoring, Interactions and Teaching

[Author Name]

School of Nursing, Purdue University Global

MN553 Advanced Pharmacology

Unit 5 Assignment

[Faculty Name]

August 11, 2026

Composite case written as a model document. No real patient, practice or prescriber is described.

What this page is doingThe title commits to a decision and to the four things a therapeutics rubric looks for: the drug, its dosing, monitoring, interactions and teaching. A reader can tell from the title alone that the paper argues for one agent rather than comparing several without concluding. The block below carries the school, the course code with its full name, and the unit line in the form students type into a search box, while the composite line settles the privacy question before the first paragraph.

Patient, Problem and Therapeutic Goal

The patient is a composite 68-year-old woman seen in a primary care practice for three months of intermittent palpitations and reduced tolerance for her usual two mile walk. An office electrocardiogram shows atrial fibrillation at a ventricular rate of 96 beats per minute, and a 14 day ambulatory monitor records a fibrillation burden of 41 percent with no pause longer than 2.5 seconds. Echocardiography reports a left ventricular ejection fraction of 58 percent, mild left atrial enlargement, and no mitral stenosis and no prosthetic valve. Her history includes hypertension for 12 years and type 2 diabetes for 6 years. Blood pressure today is 128/76 mm Hg, weight 74 kg, height 163 cm.

Two decisions follow that diagnosis and only one of them is the subject of this paper. Rate control is already adequate; the open question is stroke prevention. Her CHA2DS2-VASc score is 4, awarding one point each for age 65-74, female sex, hypertension and diabetes, which places her well above the threshold at which oral anticoagulation is recommended rather than optional (Lip et al., 2010; Joglar et al., 2024). Her HAS-BLED score is 2, driven by age and hypertension, both of which are managed. Baseline values are hemoglobin 13.2 g/dL, platelets 232 x 10^9/L, serum creatinine 0.9 mg/dL with an estimated creatinine clearance of 70 mL/min, and normal aminotransferases. She has had no gastrointestinal bleed, no intracranial hemorrhage and no fall requiring care.

What this page is doingScores are shown with their components rather than asserted. Writing out the four points that build a CHA2DS2-VASc of 4 lets a grader check the arithmetic and shows the reasoning behind the indication. Baseline laboratory values appear here, before any drug is named, because they are the inputs to the dosing rule two sheets later. Separating rate control from stroke prevention in the opening line keeps the paper to one decision, which is what a defense paper needs.

Choosing the Agent: The Case for Apixaban

The first candidate to remove is aspirin. Antiplatelet therapy is not a substitute for anticoagulation in atrial fibrillation, and offering it to a patient with a CHA2DS2-VASc of 4 trades most of the stroke reduction for very little gain in bleeding safety; current guidance advises against it as monotherapy for this indication (Joglar et al., 2024). The second candidate is warfarin, which remains the correct drug for a mechanical valve or moderate to severe mitral stenosis and is the wrong tool here, where neither is present. Warfarin would commit this patient to international normalized ratio testing, a narrow therapeutic window, and interaction with vitamin K intake and many antibiotics, without matching the direct oral anticoagulants on intracranial bleeding.

Among the direct oral anticoagulants, apixaban is defended here on three grounds. In a randomized trial of 18,201 patients with atrial fibrillation, apixaban reduced stroke or systemic embolism compared with warfarin, with less major bleeding and lower all-cause mortality (Granger et al., 2011). Its gastrointestinal bleeding profile compares favorably with the alternatives, which matters for a patient who reaches for over-the-counter naproxen when her knee hurts. Its dose reduction rule turns on three objective criteria rather than on renal function alone, which lowers the chance of an inappropriate reduction as she ages. A reversal agent for factor Xa inhibitors exists and is stocked at her regional hospital, which is a reasonable consideration in a shared decision rather than a deciding one.

The choice carries costs, and they belong in the record. Apixaban is taken twice daily, and a patient who struggles with an evening dose may do better with an agent dosed once a day, so adherence was discussed before the prescription was written rather than after the first refill. Coverage and out-of-pocket cost were checked at the visit, because an unaffordable anticoagulant is an untaken one. She was told plainly that anticoagulation raises bleeding risk, that the trade is a large reduction in disabling stroke for a smaller increase in bleeding events, and that the decision can be revisited at any point. She chose to begin therapy.

What this page is doingThe alternatives are eliminated before the choice is named, which is the structural move that turns a preference into a defense. Aspirin and warfarin each get a specific reason tied to this patient rather than a general dismissal. Trial evidence is quoted with its sample size so the claim can be weighed, and the third paragraph states the disadvantages of the chosen drug. Naming the twice daily burden and the cost check reads as clinical honesty and usually earns credit rather than losing it.

Dose Rationale, Monitoring Plan and Interactions

Dose: apixaban 5 mg orally twice daily, with or without food. The reduced 2.5 mg dose applies when a patient meets at least two of three criteria: age 80 years or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher (U.S. Food and Drug Administration, 2021). This patient meets none of them at 68 years, 74 kg and 0.9 mg/dL, so the full dose is the correct one. The error worth naming is the reflexive reduction made on age or on an impression of frailty alone, which lowers exposure below the level tested for stroke prevention and turns a proven therapy into an unproven one. The criteria were documented beside the prescription so that any future reduction has to be argued against the same three items.

Monitoring here does not mean routine coagulation testing, because neither the prothrombin time nor the international normalized ratio reflects apixaban activity usefully. What is monitored is the patient. Baseline values were drawn today; complete blood count with renal and hepatic panels are planned at 3 months and at least annually after that, with a lower threshold during any acute illness, dehydration, or new medication that changes renal clearance (Joglar et al., 2024). Blood pressure control is part of the bleeding plan rather than a separate one, since uncontrolled hypertension is the modifiable bleeding risk factor with the largest effect on intracranial hemorrhage. An unexplained fall in hemoglobin prompts evaluation for occult bleeding rather than a change in iron intake.

Two interactions were found at this visit and both were acted on. She takes naproxen sodium 220 mg, two tablets a few times a month, for knee osteoarthritis; nonsteroidal anti-inflammatory drugs add platelet inhibition and mucosal injury to anticoagulation and appear among the medications to avoid in older adults who are taking oral anticoagulants (American Geriatrics Society, 2023). Acetaminophen with a ceiling of 3 g daily was substituted and a topical agent was offered. She also takes a St. John's wort supplement begun two months ago; it induces both cytochrome P450 3A4 and P-glycoprotein, the two routes apixaban depends on, and can lower exposure enough to matter, so it was stopped. Strong dual inhibitors such as ketoconazole, itraconazole and ritonavir act on the same pathways in the opposite direction and were flagged in her record.

What this page is doingDosing is argued from stated criteria and then measured against the patient item by item, so the full dose is a conclusion rather than a default. Naming the common error, reduction on age alone, shows command of the rule. The monitoring paragraph is built around what the drug does not need as much as what it does, which prevents the routine coagulation testing that gives this drug class away. Both interactions are real findings from the history with an action attached.

Teaching Given at the Visit and Follow-Up

Teaching was given in plain language and confirmed by teach-back. Take one tablet in the morning and one in the evening at set times, with or without food. If a dose is missed, take it as soon as it is remembered on the same day, then return to the usual schedule; never take two tablets to make up for one. Do not stop the medication because a dose was missed, a tooth is being pulled or a colonoscopy has been scheduled, because stopping without a plan raises stroke risk sharply; ask first, and an interruption plan will be given. Report black or tarry stools, red or brown urine, vomit that looks like coffee grounds, bruising with no cause, gum bleeding that does not stop, or any fall in which the head is struck.

She left the visit with three things: a card naming the medication and dose to carry in her wallet, a written note for her dentist and any future surgeon, and a list of over-the-counter products to avoid, including ibuprofen, naproxen and combination cold remedies that contain them. Alcohol was discussed with a specific limit rather than a general caution. Follow-up is a telephone check at 14 days for tolerance, adherence and any bleeding, an office visit at 3 months with laboratory work, and reassessment of stroke and bleeding risk at least annually, since neither score is static (Joglar et al., 2024). Atrial fibrillation is common enough in this age group that the same conversation repeats across a panel of patients (Centers for Disease Control and Prevention, 2024).

What this page is doingTeaching is written as it was said and then confirmed by teach-back, which is what a rubric means by patient education rather than a list of facts. The missed dose instruction, the do not stop instruction and the specific bleeding signs are the three items most often left vague. The follow-up paragraph closes the loop with intervals attached to purposes, and the final citation places one patient inside a population without turning a therapeutics paper into an epidemiology paper.

References

American Geriatrics Society. (2023). American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society, 71(7), 2052-2081.

Centers for Disease Control and Prevention. (2024). Atrial fibrillation. U.S. Department of Health and Human Services. https://www.cdc.gov/heart-disease/

Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., Bahit, M. C., Diaz, R., Easton, J. D., Ezekowitz, J. A., Flaker, G., Garcia, D., Geraldes, M., Gersh, B. J., Golitsyn, S., ... Wallentin, L. (2011). Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine, 365(11), 981-992.

Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., Deswal, A., Eckhardt, L. L., Goldberger, Z. D., Gopinathannair, R., Gorenek, B., Hess, P. L., Hlatky, M., Hogan, G., Ibeh, C., Indik, J. H., Kido, K., Kusumoto, F., Link, M. S., ... Van Wagoner, D. R. (2024). 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation. Circulation, 149(1), e1-e156. https://www.ahajournals.org/journal/circ

Lip, G. Y. H., Nieuwlaat, R., Pisters, R., Lane, D. A., & Crijns, H. J. G. M. (2010). Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on atrial fibrillation. Chest, 137(2), 263-272.

U.S. Food and Drug Administration. (2021). Eliquis (apixaban) tablets: Highlights of prescribing information. https://www.accessdata.fda.gov/scripts/cder/daf/

How this MN 553 Unit 5 example is structured

In many sections this unit asks for a therapeutic decision paper: one patient, one drug chosen and defended, with dosing rationale, monitoring, interactions and teaching; your classroom's instructions and rubric decide the exact form, so read them before using this MN553 Unit 5 example as a shape. The paper narrows rather than surveys. The first sheet fixes the patient, the risk scores and the therapeutic goal so the decision has criteria to be judged against. The second sheet removes the alternatives before naming the choice, because a defense is only as strong as the options it rejects. The third sheet carries the dose rationale, the monitoring plan and the interactions found at the visit. The last sheet records the teaching given to the patient in the case, which is a record of that conversation and not advice to a reader.

MN553 Unit 5 questions, answered

What does an MN553 Unit 5 assignment usually ask for?

In many sections a mid-term pharmacology unit asks for a drug therapy paper: a patient, one agent selected and defended, with dosing rationale, monitoring parameters, interactions and patient teaching. Your classroom's instructions and rubric decide the exact form, including whether a specific drug class is assigned to you. Read the assignment page in your classroom before choosing a case.

Is it stronger to compare several drugs or to defend one?

Defend one, and eliminate the others on the way. A comparison table with no conclusion leaves the reader to do the prescribing. The structure used here removes aspirin and warfarin with patient specific reasons, names apixaban, then states the drawbacks of that choice, which shows judgment rather than preference and gives the monitoring and teaching sections something to attach to.

Which sources belong in a graduate pharmacology paper?

Use the manufacturer label or an equivalent regulatory source for dose criteria, a current specialty guideline for the indication and monitoring, and at least one primary trial for efficacy claims. Add a safety source, such as prescribing criteria for older adults, when age is part of the case. Tertiary drug databases can inform your reading but rarely carry a graduate reference list on their own.

Write yours, or have the desk draft it

This paper is an original model document written by our desk, not a submitted student paper and not an official Purdue University Global document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.

MN553 Unit 5: sample paper, in real form